Supplements
Fadogia agrestis went viral after a Huberman Lab mention. The evidence is entirely from rodents, it includes testicular and liver toxicity at high doses, and no human trials exist.
Key takeaways
Fadogia agrestis went from obscure West African shrub to supplement-store staple almost overnight. One mention on the Huberman Lab podcast and the testosterone optimization community was sold. But the honest picture is more complicated — and significantly more interesting — than the hype suggests.
This article covers what Fadogia agrestis actually does in the available research, what the real safety concerns are, how it compares to better-studied alternatives, and who (if anyone) should consider it.
Fadogia agrestis is a shrub native to Nigeria and other parts of West and Central Africa. Traditionally, it was used in folk medicine as an aphrodisiac and general vitality tonic — a common cultural use pattern shared with many plants that later attract pharmacological interest.
The plant’s stems are the part most commonly studied. Extracts from the stems have been analyzed for alkaloids, saponins, anthraquinones, and flavonoids — a phytochemical profile consistent with many African medicinal plants. None of these components have been isolated and studied in humans in a way that explains a specific testosterone mechanism.
That said, something in the plant appears to influence luteinizing hormone (LH) and testosterone production in rodent models. That’s the kernel of evidence underlying the hype — and it’s worth examining carefully.
The most-cited Fadogia agrestis research comes from a 2005 paper by Yakubu and colleagues (Asian Journal of Andrology). In this study, male rats were given aqueous stem extract at doses of 18, 36, or 100 mg/kg body weight per day for 28 days. The key findings:
A follow-up 2008 study by the same group found that testicular histology remained intact at standard doses, but showed signs of toxicity at very high doses — a finding that becomes critical in the safety section below.
Using the standard body-surface-area conversion (rat Km 6 / human Km 37), the 18 mg/kg rat dose corresponds to roughly 200–235 mg/day for a 70–80 kg adult; simple weight scaling would give about 1,260–1,440 mg/day. Most commercial supplements contain 600–1,200 mg per serving — a range where the relevant pharmacokinetics and effects in humans are completely unknown.
There are currently no published human clinical trials on Fadogia agrestis and testosterone. Zero. The entire human case rests on rodent data and anecdotal reports.
This doesn’t mean the effect doesn’t exist in humans. It means we don’t know. That distinction matters.
This is where honest coverage of Fadogia agrestis diverges sharply from most supplement marketing.
The same 2005 Yakubu paper that reported testosterone increases also found concerning testicular changes at higher doses. At 100 mg/kg in rats, microscopic examination showed distorted seminiferous tubule architecture and reduced sperm count parameters.
A 2009 study (Omotola et al.) specifically investigated reproductive toxicity in male rats and found: - Increased testicular malondialdehyde (a marker of oxidative stress) at higher doses - Degenerative changes in spermatogenic cells at doses used to produce testosterone increases - Reduced sperm motility and viability with prolonged exposure
The implication: the same doses that appear to boost testosterone in the short term may cause oxidative damage to testicular tissue with sustained use. This is a dose-response curve with a concerning shape — beneficial effects at lower doses, potentially harmful structural changes at doses that aren’t dramatically higher.
A 2010 study by Ajagbonna and colleagues found elevated liver enzymes (ALT, AST) in rats given Fadogia agrestis extract, suggesting potential hepatic stress. The effect was dose-dependent and reversible after discontinuation, but the signal is worth noting given how common “stack” use is — combining Fadogia with other supplements with their own liver considerations.
Wild-harvested botanical extracts can carry heavy-metal contamination, depending on soil composition and the absence of standardized agricultural controls. No published data exists on typical contamination levels in commercial Fadogia agrestis products. Third-party testing by reputable brands helps, but this is a category where supply chain transparency is genuinely limited.
The longest animal study on Fadogia is approximately 28 days. There is no 6-month or 12-month safety data in any species. Given the theoretical testicular oxidative stress signals, this gap is meaningful.
The most common use pattern is co-administration with Tongkat Ali (Eurycoma longifolia), a pairing popularized by Andrew Huberman. The theoretical logic:
This upstream/downstream combination has theoretical appeal. The problem is that the Tongkat Ali evidence is substantially stronger — multiple human RCTs exist for Tongkat Ali, while Fadogia remains at the rodent-data stage.
If budget or simplicity is a consideration, Tongkat Ali alone has a more robust evidence base for the same core goal.
Given the oxidative stress signals at sustained doses in rodents, many practitioners who use Fadogia recommend cycling (e.g., 8 weeks on, 4 weeks off). This is a reasonable precaution given the available data, but it’s worth noting that cycling protocols are based on precautionary reasoning rather than human evidence for harm.
| Compound | Human RCTs? | Effect in Humans | Safety Profile |
|---|---|---|---|
| Tongkat Ali | Yes (several RCTs) | Modest testosterone + SHBG reduction | Generally favorable |
| Ashwagandha | Yes (≥6 RCTs) | Testosterone, LH, sperm quality | Extensive data, generally safe |
| Zinc | Yes | Corrects deficiency-driven decline | Excellent (within dosing range) |
| Boron | Yes (small trials) | SHBG reduction, modest T increase | Favorable |
| Fadogia Agrestis | No | Unknown in humans | Concerning signals at higher rodent doses |
| D-Aspartic Acid | Yes (mixed) | Short-term spike, unclear sustained effect | Neutral |
The pattern is clear: Fadogia is the most evidence-poor option in the testosterone stack category, and it also has the most concerning safety signals. That doesn’t make it useless — rodent data is a legitimate starting point — but it means the risk-benefit calculation is different from compounds where human data exists.
The honest answer is: we don’t know.
The anecdotal reports are real — many users report subjective increases in libido, energy, and “drive” within 1–2 weeks of starting Fadogia supplementation. These could represent:
Without a controlled trial, individual reports cannot separate these possibilities; a clinician-ordered testosterone panel before and after use is the only objective check.
No human dose has ever been studied. Commercial products typically supply 400–600 mg/day and users often cycle 8 weeks on, 4 off; none of this is validated. Talk to a clinician before use, especially if you take medications or have liver concerns.
Since no human dose-ranging data exists, the following represents common practice with the caveat that it’s not evidence-validated:
Typical dose: 400–600 mg/day of standardized stem extract
Cycle: 8 weeks on, 4 weeks off (precautionary cycling)
Timing: Morning, with food
Co-administration: Often paired with 400–600 mg Tongkat Ali daily
Tracking: Baseline and post-cycle bloodwork (total T, free T, SHBG, LH, FSH, liver enzymes)
What to look for on bloodwork (signs of potential concern): - Elevated ALT/AST (hepatic stress signal) - Suppressed LH/FSH (paradoxical downregulation if dosing is excessive) - Any symptom of testicular discomfort
Fadogia agrestis is fascinating precisely because it’s at the edge of the known. The rodent testosterone data is real, the mechanism is plausible, and the community interest is understandable. But the safety signals — particularly the testicular oxidative stress data at doses near the effective range — deserve more attention than most reviews give them.
The compound might become interesting if well-designed human trials emerge. Until then, the risk-adjusted recommendation is straightforward: if testosterone optimization is the goal, the evidence base for Tongkat Ali, Ashwagandha, and the core testosterone stack is substantially stronger, and the safety profiles are substantially cleaner.
Anyone who still chooses to try it is operating without human data; discuss it with a clinician first and get baseline and follow-up bloodwork.
This article is for general education and is not medical advice.
Related
Supplements
Three COSMOS sub-studies found a daily multivitamin nudged memory scores in adults over 60. How big the effect is, why an earlier trial found nothing, and where cancer, heart and lifespan data stand.
Supplements
Your endocannabinoid system helps regulate pain and inflammation. What reviews and surveys report about hemp-derived plant compounds, and where the evidence stops.
Supplements
Human trials link bovine colostrum to lower gut permeability, fewer respiratory symptoms in hard-training athletes and modest lean-mass gains. The doses used, the limits and the safety picture.
Readers
Comments
Leave a comment